Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Conference Forum's Immuno-Oncology 360° Announces the Support of Key Partnerships to Present Multiple Views to Advance IO as a Standard of Cancer Treatment
  • USA - English


News provided by

IO360/The Conference Forum

Nov 19, 2015, 08:20 ET

Share this article

Share toX

Share this article

Share toX


New York, New York (PRWEB) November 19, 2015 -- The Conference Forum announced today that the Cancer Research Institute (CRI), Society of Immunotherapy for Cancer (SITC) and The Association for Cancer Immunotherapy (CIMT) are supporting partners of the 2nd Annual Immuno-Oncology 360° (IO360°) conference, the only conference combining the most current business, clinical and scientific developments to help accelerate clinical trials and FDA approval in the growing space of cancer immunotherapies, taking place February 2-3, 2016 at The New York Academy of Medicine, NY.

The Immuno-Oncology 360° program will help drive the field of cancer immunotherapy through knowledge sharing and disseminating the most current data, innovative approaches and developments that are changing the way cancer is treated

Post this

“With the support of CRI, SITC and CIMT, the Immuno-Oncology 360° program will help drive the field of cancer immunotherapy through knowledge sharing and disseminating the most current data, innovative approaches and developments that are changing the way cancer is treated,” said Kate Woda, Conference Director for the Immuno-Oncology 360° program.

The Immuno-Oncology 360° program is developed by lead advisors, Dr. Axel Hoos, VP of Oncology R&D, GlaxoSmithKline and Dr. James Gulley, Head of Immunotherapy Section at the National Cancer Institute along with input from industry, academia, the investment community, research organizations and government.

“We are undergoing a radical change in cancer treatment, and the biopharma industry needs to gain information that will be beneficial for industry and patients,” said Axel Hoos, MD, PhD “The conference will deal with a panoply of topics, including the investment landscape and key business deals, combination immunotherapies and how to test them in clinical trials, and what role the patient can have on clinical designs and recruitment procedures.”

The conference features national and international experts including but not limited to Dr. Carl June, Director of Translational Research, University of Pennsylvania, Dr. Jedd Wolchok, Chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, and Dr. Alexander Eggermont, Director General, Institut Gustave Roussy.

The speaking faculty at Immuno-Oncology 360° includes:

  • Anne Altmeyer, PhD, MBA, MPH, VP, Business Development & Licensing, Head Negotiations, Oncology, Baxalta
  • Robert Ang, MD, MBA, Chief Business Officer, Neon Therapeutics
  • Philippe Armand, MD, PhD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute
  • Roy Baynes, MD, PhD, SVP, Global Clinical Development, MercK Research Labs
  • Kenneth Bloom, MD, FACP, Chief Medical Officer, GE Healthcare
  • Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, FDA, CDER, FDA
  • Cedrik Britten, MD, Head of Cell Therapy, GlaxoSmithKline
  • Alexander Eggermont, MD, PhD, Director General, Institut Gustave Roussy
  • Mark Frohlich, MD, EVP, Development and Portfolio Management, Juno Therapeutics
  • Winald Gerritsen, Professor and Medical Oncologist, Radboud Medical Center, Nijmegen
  • John Graham, MB, ChB, FRCR, FRCP, Manager / Director, National Institute of Clinical Excellence (NICE) / National Collaborating Centre for Cancer
  • James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
  • Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute
  • Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline
  • Ramy Ibrahim, MD, Clinical VP of Immuno-Oncology, AstraZeneca
  • Carl June, MD, Director, Translational Research Program; Professor of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania
  • Michael Kalos, PhD, CSO, Cancer Immunobiology, Eli Lily
  • Howard Kaufman, MD, FACS, Chief Surgical Officer, Assoc. Director / President, Rutgers Cancer Institute of New Jersey / Society for Immunotherapy of Cancer (SITC)
  • Herbert Kim Lyerly, MD, Professor Surgery, Assistant Professor in Immunology, Associate Professor of Pathology, Duke Cancer Center
  • Michael King Jr, Managing Director and Senior Biotech Analyst, JMP Securities
  • Ron Korn, MD, PhD, Founder, Chairman and CMO, Imaging Endpoints
  • Philippe Lopes Fernandes, SVP & Head of Global Licensing & Business Development, Merck KGaA
  • Kamala Maddali, DVM, PhD, VP, Biopharma Collaborations & Companion Diagnostics Cancer Genetics Inc.
  • Patricia Marinello, PharmD, Clinical Director, Oncology Clinical Research, Merck Research Labs
  • Ian McCaffery, PhD, Head, Companion Diagnostics, Oncology Biomarker Development, Genentech
  • RJ Motzer, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center
  • Andrea Perrone, MD, Head, Imaging, Merck
  • Reena Philip, PhD, Division Director Division of Molecular Genetics and Pathology (DMGP) Office of In Vitro Diagnostics and Radiological Health CDRH, FDA
  • David Reese, MD, SVP, Translational Sciences, Amgen
  • Naiyer Rizvi, MD, Director, Thoracic Oncology & Immunotherapeutics in Medical Oncology, NY Presbyterian / Columbia University Medical Center
  • Eric Rubin, MD, Vice President, Global Clinical Oncology, Merck Research Labs
  • Rita Shaknovich, MD, PhD, Medical Director and VP of Hematopathology, Cancer Genetics Inc.
  • Mark Simon, Partner, Torreya Partners
  • Robert Stein, MD, PhD, Chief Science Officer, Agenus
  • Marc Theoret, MD, Lead Medical Officer, Office of Oncology Drug Products, CDER, FDA
  • Peter Thompson, MD, FACP, Private Equity Partner, OrbiMed Advisors
  • Jeffrey Weber, MD, PhD, Senior Member and Director Donald A Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center
  • Kari Whitehead, MS, RD, Co-founder, Emily Whitehead Foundation
  • Jedd Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service; Lloyd J. Old Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center
  • Cissy Young, Executive Director, Russell Reynolds Associates

For more information about the Immuno-Oncology 360° program, visit http://theconferenceforum.org/conferences/immuno-oncology-360/overview/

About The Conference Forum:
The Conference Forum develops specialized events for professionals in the life science and healthcare industries. We currently offer conferences for R&D leaders, clinical development professionals, biotech executives, VCs, drug delivery specialists and pharma/generic government directors. Our mission is to create the best content, exchange ideas and solutions among peers and provide quality networking for Pharmaceutical and Biotech professionals. http://www.theconferenceforum.org

About Cancer Research Institute (CRI):
Cancer Research Institute is a nonprofit organization dedicated exclusively to the advancement of immunotherapy for cancer. It raises funds and provides research grants to laboratory and clinical scientists who are progressing this field. It also connects patients with cancer immunotherapy clinical trials and with other patients and caregivers considering treatment with immunotherapy. http://www.cancerresearch.org/

About Society for Immunotherapy of Cancer (SITC):
SITC is a 501 (c)(3) non-profit medical professional society of influential scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. http://www.sitcancer.org

About The Association for Cancer Immunotherapy (CIMT):
The Association for Cancer Immunotherapy (CIMT) is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT was founded in 2002 by physicians and researchers from different fields of clinical and theoretical medicine as an independent non-profit organization. CIMT has its offices in Mainz, Germany, and is financed by donations, congress fees, industry sponsorship and by public and foundation grants. http://www.cimt.eu/

Jessica Rothenberg, IO360/The Conference Forum, http://www.theconferenceforum.org, 646-490-2712, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.